Join Medicilon at Frontiers in Peptide Science and Drug Discovery Symposium

We are excited to announce that Medicilon is honored to be the title sponsor at Frontiers in Peptide Science and Drug Discovery Symposium. The symposium will take place on 5 August 2022 at the School of Biological Sciences Classroom 1, Nanyang Technological University (NTU), Singapore. Our CEO Dr. Chun-Lin Chen will be sharing his presentation on "Bioanalytical Challenge & Strategy for Peptide Drugs".

We welcome you to join us at the forum! Please stop by our booth and chat how our services and capabilities would support your research needs and expedite your drug discovery and development programs.

Date: 5 August 2022

Location: Nanyang Technological University, Singapore.

Frontiers in Peptide Science and Drug Discovery Symposium

The symposium is jointly organised by the School of Biological Sciences and the NTU-Institute of Advanced Studies (NTU-IAS). It will cover many exciting fields of peptide and protein research including chemistry, structure and function, and applications in medicine and materials science.

The symposium would provide a platform for our participants to present and learn about the current forefront of peptide / protein science and drug discovery; as well as to exchange ideas and establish research collaborations or business relations across both academia and industry. To learn more, please visit their website. 

Medicilon Peptide Research Service

Medicilon peptide synthesis research team is closely focused on the topic of peptide drug research and is committed to solving the core problems that limit the development and application of peptide drugs. To improve the downstream peptide drug signal transduction pathways and mechanisms of action to improve the system. Through multi-disciplinary cooperation and intersections in chemistry, biology, medicine, and pharmacy, outstanding achievements have been made in basic and applied research.

Peptide Synthesis Services:

❖ Standard chemical peptide synthesis

❖ Peptide modification

❖ Peptide library

❖ Recombinant polypeptide expression

❖ Pharmaceutical peptide synthesis

❖ Structural modification

❖ Nuclear magnetic structure analysis

❖ Function test

Medicilon biotechnology drug analysis research team uses ELISA, ECL, TRFIA, CLIA, IF, IP, CoIP, qPCR, FACS, ELISpot, enzymology and other methods to support cutting-edge biological drugs such as proteins, antibodies, ADC, peptides, nucleic acids, vaccines and cell gene therapy and other drugs in the early development, preclinical and clinical stages of PK/TK/Immunogenicity/Biomarker&Cytokine and other research evaluations. Research work in different stages of peptide drugs for cardiovascular, bone, tumor and other related diseases. Medicilon looks forward to cultivating in the field of peptides, empowering more innovative pharmaceutical companies, and relying on R&D capabilities to help the human health industry develop vigorously.

Medicilon Drug Discovery Services

Medicilon is an integrated contract research organization (CRO), providing comprehensive one-step new drug R&D for pharmaceutical enterprises and scientific research institutions around the world. We provide one-stop customized R&D solutions ranging from precise drug targeting to IND filing assistance.Deeply integrate R&D experience, constantly climb the peak of R&D technology, and build an integrated innovation service platform for new drug R&D.

Medicilon Drug discovery services include chemistry (synthetic chemistry, medicinal chemistry) and biology. In terms of chemistry, it can undertake multi-dimensional business such as custom synthesis, compound library construction, SAR compound synthesis and screening, compound structure and biological activity optimization.

The medicinal chemistry team deeply cross-integrates chemistry and biology into each project, and flexibly uses the powerful expertise of computational chemistry to aid the compound design process. At the same time, Medicilon extensively uses advanced drug discovery technology, including PROTAC targeted protein degradation technology, DEL DNA-encoded small molecule compound library screening technology, ADC antibody drug conjugation technology, etc. Medicilon efficiently promotes customers' drug research and development projects, controls costs, and improves quality!